Gastric Cancer | Topics

Limited Clinical Activity Attributed to Second-Line Treatment With Linagliptin Plus Atezolizumab in Gastric/GEJ Carcinoma
September 16, 2021

Findings from the phase 1b/2 MORPHEUS study indicated that patients with gastric and gastroesophageal junction cancer experienced limited responses to second-line linagliptin plus atezlolizumab.

Certain Genomic Pathways of Gut Microbiome Significantly Associated With Survival in Nivolumab-Treated Patients With Gastric/GEJ Cancer
September 02, 2021

Data from patients with gastric or gastroesophageal junction cancers who were treated with nivolumab showed that effects in the genomic pathways of the gut microbiome may be significantly associated with survival.

Perioperative Oxaliplatin With S-1 Demonstrates Significant Clinical Activity in Locally Advanced Gastric Cancer
August 23, 2021

Research suggests that perioperative S-1 plus oxaliplatin in patients with gastric cancer who have had a D2 gastrectomy yields a clinically significant improvement over adjuvant capecitabine plus oxaliplatin.

Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Effective in Korean Population With Advanced Gastric Cancer
July 26, 2021

Recent data indicated that the combination of neoadjuvant docetaxel, oxaliplatin, and S-1 followed by surgery and adjuvant S-1 was effective and tolerable in a population of Korean patients who had locally advanced gastric cancer.

Merck to Withdraw Indication for Pembrolizumab in Third Line Gastric Cancer
July 07, 2021

The pharmaceutical company plans to voluntarily withdraw the accelerated approval indication for pembrolizumab in the third line setting for patients with gastric cancer within the coming months.

FDA Approves Nivolumab Plus Chemo for Frontline Advanced Gastric Cancer
April 16, 2021

The agency approved nivolumab in combination with certain types of chemotherapy for the initial treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma, making it the first approved first-line immunotherapy for this patient population.

Nivolumab Plus Paclitaxel Shows Clinical Activity in Advanced Gastric Cancer Subgroup
April 10, 2021

Nivolumab in combination with paclitaxel showed clinical activity and a manageable safety profile when used as second-line therapy for patients with Epstein-Barr virus–related, microsatellite instability–high/mismatch repair deficient or PD-L1–positive advanced gastric cancer.

Trastuzumab Deruxtecan Sensitivity Associated With Various Levels of HER2-Expressing Gastric Cancer Cells
April 10, 2021

Trastuzumab deruxtecan has not only demonstrated efficacy as a potential anti-HER2 therapeutic option for patients with HER2-amplified gastric cancers, but has also shown promise in those with HER2 moderate-, low-, and non-expressing disease.

Early-Onset Gastric Cancer Suggested to be Genetically and Clinically Distinct
January 20, 2020

Incidence of early-onset gastric cancer has steadily increased in the US, now comprising >30% of new gastric cancer cases today, causing researchers to try and discover what makes this disease type unique.

Combo Therapy Shows Modest Survival Gain, More Toxicity for Gastric Cancer
October 22, 2019

A combination of trifluridine and tipiracil showed some gains in overall survival for patients with metastatic gastric cancer or gastroesophageal junction cancer.